 |
 |

Risk-Treatment Paradox in Use of Statins
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
To the Editor: Dr Ko and colleagues1 reported that the probability of receiving statin treatment actually decreases with increasing age and baseline risk for coronary heart disease. The authors defined baseline risk as the probability of death from any cause within 3 years. In high-risk older patients, death can be considered as a competing risk, and it has been recommended that limited life expectancy be factored into the creation of health care plans.2-3 Usually, death from cardiovascular disease is the most common form of an event that removes the risk of a different event. In this case, death from any cause can compete with the probability of benefit from statin therapy.
Ko et al reported 60% three-year mortality in their highest-risk subgroup. In the United States the average life expectancy of an individual who reaches the age of 95 years is still 3.6 years,4 suggesting that most high-risk older individuals . . . [Full Text of this Article]
Carlos O. Weiss, MD
cweiss9@jhmi.edu
Ravi Varadhan, PhD
Johns Hopkins Center on Aging and Health Baltimore, Md
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
RELATED ARTICLES
Risk-Treatment Paradox in Use of StatinsReply
Dennis T. Ko and David A. Alter
JAMA. 2004;292(2):169.
EXTRACT
| FULL TEXT
Lipid-Lowering Therapy With Statins in High-Risk Elderly Patients: The Treatment-Risk Paradox
Dennis T. Ko, Muhammad Mamdani, and David A. Alter
JAMA. 2004;291(15):1864-1870.
ABSTRACT
| FULL TEXT
Cancer Screening in Elderly Patients: A Framework for Individualized Decision Making
Louise C. Walter and Kenneth E. Covinsky
JAMA. 2001;285(21):2750-2756.
ABSTRACT
| FULL TEXT
|